首页> 外文期刊>Addiction Science & Clinical Practice >Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder
【24h】

Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder

机译:从监禁中释放,复发至使用阿片类药物以及丁丙诺啡维持治疗的潜力:对以前患有阿片类药物使用障碍的人的认知的定性研究

获取原文
           

摘要

Background The United States has the highest rate of incarceration in the world (937 per 100,000 adults). Approximately one-third of heroin users pass through correctional facilities annually. Few receive medication assisted treatment (MAT; either methadone or buprenorphine) for opioid use disorder during incarceration, and nearly three-quarters relapse to heroin use within 3?months of release. This qualitative study investigated barriers to and facilitators of buprenorphine maintenance treatment (BMT) following release from incarceration (“re-entry”). Methods We conducted 21 semistructured interviews of former inmates with opioid use disorder recruited from addiction treatment settings. Interviews were audio-recorded, transcribed, and analyzed using a grounded theory approach. Themes that emerged upon iterative readings of transcripts were discussed by the research team. Results Participants reported adverse re-entry conditions, including persistent exposure to drug use and stressful life events, which were perceived to contribute to opioid relapse and affected addiction treatment decisions during re-entry. Themes that emerged relating to BMT included: 1) reliance on willpower; 2) fear of dependency on medications; 3) variable exposure to buprenorphine; and 4) acceptability of BMT following relapse. Willpower was perceived to be more important for recovery than medications. Many participants experienced painful withdrawal from methadone during incarceration and were fearful that using MAT would lead to opioid tolerance and painful withdrawal again in the future. Participants reported both positive and negative experiences taking illicit buprenorphine, which affected interest in BMT. Overall, BMT was perceived to be a good treatment option for opioid use disorder that could reduce the risk of re-incarceration. Conclusions BMT was perceived to be acceptable, but former inmates with opioid use disorder may be reluctant to utilize BMT upon re-entry. Factors limiting utilization of BMT could be mitigated though policy change or interventions. Policies of the criminal justice system (e.g., forced detoxification) may be dissuading former inmates from utilizing effective treatments for opioid use disorder. Interventions that improve education and access to BMT for former inmates with opioid use disorder could facilitate entrance into treatment. Both policy changes and interventions are urgently needed to reduce the negative consequences of opioid relapse following re-entry.
机译:背景技术美国的监禁率是世界上最高的(每10万人中有937人)。每年约有三分之一的海洛因使用者通过教养所。很少有人在监禁期间因阿片类药物使用障碍而接受药物辅助治疗(MAT;美沙酮或丁丙诺啡),在释放后的3个月内,将近四分之三的海洛因使用率复发。这项定性研究调查了从监禁释放后(“再次进入”)丁丙诺啡维持治疗(BMT)的障碍和促进因素。方法我们对从成瘾治疗场所招募的前阿片类药物使用障碍的囚犯进行了21次半结构式访谈。使用扎根的理论方法对访谈进行录音,转录和分析。研究小组讨论了在反复阅读成绩单时出现的主题。结果参与者报告了不良的再入病情况,包括持续暴露于药物使用和紧张的生活事件,这被认为会导致阿片类药物复发并影响再入过程中的成瘾治疗决定。与BMT相关的主题包括:1)对意志力的依赖; 2)害怕依赖药物; 3)丁丙诺啡的暴露量可变; 4)复发后BMT的可接受性。人们认为,意志力对康复而言比药物更为重要。许多参与者在监禁期间经历了美沙酮的痛苦戒断,并担心使用MAT会导致阿片类药物的耐受性以及将来再次痛苦戒断。参与者报告了服用非法丁丙诺啡的积极和消极经历,这影响了对BMT的兴趣。总体而言,BMT被认为是阿片类药物使用障碍的一种很好的治疗选择,可以减少再次被监禁的风险。结论BMT被认为是可以接受的,但患有阿片类药物使用障碍的前囚犯可能不愿在再次进入时使用BMT。可以通过政策变更或干预措施来缓解限制BMT使用的因素。刑事司法系统的政策(例如,强制排毒)可能会阻止前囚犯对阿片类药物使用障碍采取有效的治疗措施。改善患有阿片类药物使用障碍的前囚犯的教育和获得BMT的干预措施可以促进进入治疗。迫切需要改变政策和采取干预措施,以减少再次进入阿片类药物后的不良后果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号